Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention

This article was originally published in RPM Report

Executive Summary

Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.

You may also be interested in...



Part D and the Exchanges: Not A Perfect Analogy

In the run up to its launch in 2006, Part D was politically controversial and there was considerable skepticism about the logistical challenges for implementation. That experience is reassuring for implementers of the Affordable Care Act – but advocates should be wary of relying too much on parallels to Part D.

Medicare Rebates: Bigger is Better, But is Big Government Best?

An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.

Medicare Rebates: Bigger is Better, But is Big Government Best?

An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel